After careful deliberations, the CHMP considered that the clinical data to support the add-on therapy in very young children are sufficient for approval, taking into account that this formulation was approved for use in children aged 6 months to 2 years in approximately 52 countries, including 17 of 27 European Union (EU) Member States (first approval in 2002) plus Iceland and Norway.